Studies utilizing microfluidic-based EVs decorated with melanoma tumor peptides (glycoprotein-100, MART-1, and MAGE-A3) on the EV surface revealed an enhanced ability for antigen presentation and T-cell activation [44, 54, 58] [54, 55, 58], with activation of glycoprotein-100-specific CD8+ T cells and effective reduction of melanoma tumor volume in mice [42, 54, 58]. This evidence concerns the gene CD8A and melanoma.